What is the recommended workup and management for an incidental pulmonary interstitial lung abnormality (ILA)?

Management of Incidental Pulmonary Interstitial Lung Abnormalities (ILA)

When you discover an incidental ILA on chest CT, perform baseline symptom assessment (cough and dyspnea on exertion) and pulmonary function testing (FVC, TLC, DLCO), then schedule follow-up chest CT in 2-3 years—but avoid invasive procedures, genetic testing, or lung biopsy at baseline. 1

Initial Workup Algorithm

Step 1: Confirm the ILA Diagnosis

The radiologist must verify that CT findings show:

• Bilateral, nondependent ground-glass opacities, reticular abnormalities, lung distortion, traction bronchiectasis, and/or honeycombing
• Involving >5% of any lung zone (not ≤5%)
• Findings persist on prone imaging if initially seen only in dependent areas 1

Step 2: Baseline Clinical Assessment (DO THIS)

Perform these three assessments immediately: 1

1. Symptom Assessment: Specifically ask about:

   • Cough (dry or productive)
   • Dyspnea on exertion (quantify activity level that triggers it)

2. Pulmonary Function Testing: Measure all three:

   • FVC (forced vital capacity)
   • TLC (total lung capacity)
   • DLCO (diffusing capacity)

   This establishes baseline for future comparison and identifies early ILD that may not yet be symptomatic.

3. Risk Factor Evaluation: Document:

   • Smoking history
   • Family history of pulmonary fibrosis
   • Connective tissue disease
   • Occupational/environmental exposures

Step 3: What NOT to Do at Baseline

Avoid these tests unless specific indications exist: 1

• No lung biopsy or bronchoscopy (97% consensus against)—the harm from invasive procedures outweighs benefit when diagnosis is uncertain
• No MUC5B genetic testing (97% consensus against)—not clinically actionable at this stage
• No telomere length measurement (97% consensus against)—expensive, not widely available, doesn't change management

Exception: Consider telomere testing only if family history or clinical features (early graying, liver disease, cytopenias) suggest telomeropathy 1

Follow-Up Strategy

Standard Surveillance

Schedule repeat chest CT in 2-3 years for most patients with ILA 1

This interval balances:

• Early detection of progression
• Avoiding excessive radiation exposure
• Cost-effectiveness

Accelerated Surveillance (12-month follow-up)

Consider earlier CT if patient has: 2

• Subpleural fibrotic pattern (traction bronchiectasis/honeycombing)—highest progression risk
• Basal and peripheral predominance
• Symptoms (cough, dyspnea)
• Abnormal PFTs at baseline
• High-risk features: age >60, current smoking, family history of pulmonary fibrosis

Risk Stratification for Progression

High-Risk Features (Monitor Proactively)

Patients with these features warrant closer follow-up: 3, 4, 2

• Subpleural fibrotic ILA subtype (vs. nonsubpleural or subpleural nonfibrotic)
• Basal and peripheral distribution
• Larger extent of lung involvement
• Declining PFTs
• Progressive symptoms
• MUC5B promoter variant (if known)
• Age >60 years
• Active smoking

Lower-Risk Features (Monitor Reactively)

• Nonsubpleural pattern
• Stable or absent symptoms
• Normal PFTs
• Younger age
• No smoking history

When ILA Becomes ILD

Transition to ILD diagnosis occurs when: 1, 2

• Definite fibrosis (honeycombing and/or reticulation with traction bronchiectasis) involves >5% of total lung volume
• OR symptomatic respiratory disease attributable to imaging findings
• OR physiologic impairment (reduced FVC, TLC, or DLCO) attributable to imaging findings

At this point, refer to pulmonologist for ILD-specific management per existing ILD guidelines.

Special Populations Requiring Screening

Proactively screen these high-risk groups with baseline chest CT: 1

1. Smokers undergoing lung cancer screening—systematically assess for ILA on every scan
2. Connective tissue diseases: rheumatoid arthritis, systemic sclerosis, polymyositis, dermatomyositis, antisynthetase syndrome, mixed CTD, Sjögren's disease
3. Family history: Adults ≥50 years with first-degree relative with familial pulmonary fibrosis (≥2 relatives with fibrotic ILD)

Common Pitfalls to Avoid

1. Don't confuse dependent atelectasis with ILA—confirm findings persist on prone imaging 1

2. Don't rush to biopsy—the 2025 ATS guidelines strongly recommend against invasive sampling at baseline ILA stage 1

3. Don't order genetic testing reflexively—MUC5B and telomere testing don't change initial management and aren't universally available 1

4. Don't use the same follow-up interval for all patients—risk-stratify based on imaging pattern, symptoms, and PFTs 2

5. Don't ignore unilateral findings in high-risk patients—family history or known genetic variants may still indicate risk even with unilateral changes 1

Practical Implementation

The 2025 American Thoracic Society guidelines 1 represent the most current, high-quality evidence with near-unanimous consensus (94-100% approval). These recommendations prioritize noninvasive early identification while avoiding harm from unnecessary procedures. The approach balances detecting progressive disease early enough to intervene while preventing overtreatment of stable, benign findings.

The key is establishing a baseline (symptoms + PFTs + imaging characteristics) and then monitoring for change rather than aggressively pursuing diagnosis in asymptomatic patients with minimal findings.